studygraphics
#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema
Mar 30, 2022
Patients with hereditary angioedema receiving donidalorsen showed reduced rates of angioedema...
Read More#VisualAbstract: Non-severe tuberculosis in children can be treated with a shorter 4-month regimen instead of 6-month regimen
Mar 27, 2022
For children with non-severe tuberculosis, 4 months of antituberculosis treatments was...
Read More#VisualAbstract:
Mar 23, 2022
Three Covid-19 vaccines from Pfizer, Moderna, and Johnson & Johnson provided durable...
Read More#VisualAbstract: Pertuzumab plus trastuzumab significantly improves survival in metastatic breast cancer
Mar 23, 2022
Click to read this study in JAMA Network Open.
Read More#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas
Mar 23, 2022
Click to read this study in the Journal of the American Academy of...
Read More#VisualAbstract: Differences in Merkel cell carcinoma recurrence and survival rates stratified by cancer stage
Mar 15, 2022
Click to read this study in JAMA Dermatology.
Read More#VisualAbstract: Peanut oral immunotherapy desensitizes young children with non-anaphylactic peanut allergies
Mar 11, 2022
Compared to placebo, children who received peanut oral immunotherapy experienced significantly...
Read More#VisualAbstract: Endotracheal intubation offers no benefit over supraglottic airway in patients with out-of-hospital return of spontaneous circulation
Mar 9, 2022
Rates of sustained return of spontaneous circulation after non-traumatic out-of-hospital cardiac...
Read More#VisualAbstract: No difference in survival between fluorouracil, cisplatin, or carboplatin-based paclitaxel therapy for locally advanced esophageal squamous cell carcinoma
Mar 9, 2022
Click to read this study in JAMA Network Open.
Read More#VisualAbstract: Delayed receipt of adjuvant hormone therapy is associated with worse survival in HR⁺, ERBB2- breast cancer
Mar 9, 2022
Click to read this study in JAMA Network Open.
Read More#VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19
Mar 4, 2022
1. All-cause mortality at 28 days was significantly higher in the usual care group compared to the...
Read More#VisualAbstract: Capecitabine in addition to best supportive care improves progression-free survival in metastatic nasopharyngeal carcinoma
Mar 3, 2022
Click to read this study in JAMA Oncology.
Read More#VisualAbstract: Cutaneous squamous cell carcinoma with satellitosis or in-transit metastasis shows similar survival to node-positive disease
Mar 2, 2022
Click to read this study in JAMA Dermatology.
Read More